Trending...
- Boston: Disparity study completed; executive order signed establishing goals for minority- and woman-owned businesses
- Boston: Mayor Walsh announces completion of disparity study, signs executive order establishing goals for minority- and woman-owned businesses
- Legacy Gospel Series Project - New Previously Unreleased Recordings
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, a global leader committed to innovating for a healthier world, today announced the addition of new assay kits to help further GPCR (G Protein-Coupled Receptor) therapeutic discovery. The new PerkinElmer offerings extend the company's leading GPCR analysis portfolio, which includes innovative assays, plate readers, automation technologies and software solutions combined with siRNA, shRNA, CRISPR, and cDNA/ORFlibraries to help scientists more easily and accurately characterize receptors, screen compounds and streamline workflows.
The new assays, which enable researchers to use the preferred cell models of their choice, include the HTRF GTP Gi binding kit, the industry's first TR-FRET based assay for GTP binding; the B-arr2 recruitment kit; and HTRF total kits for B-Arrestin 1, B-Arrestin 2 and AP2. These assays will help scientists continue to better understand the important role GPCRs play in disease by studying the interaction, expression and potential modulation of intracellular proteins involved in GPCR signaling mechanisms.
More on Boston Chron
Further, when the new kits are leveraged as part of PerkinElmer's comprehensive range of GPCR solutions, users can fully characterize the GPCRs being studied -- from ligand binding with the Tag-Lite® platform, and 2nd messenger with the cAMP and IP-One™ kits, to downstream GPCR signaling with hundreds of available assays. With the recent acquisition of Horizon Discovery, the PerkinElmer portfolio also includes siRNA, shRNA, CRISPR guide RNA, and cDNA/ORF libraries, such as ON-TARGETplus™, SMARTvector™ and Edit-R™ and screening services, which help researchers better explore the impact of gene modulation and editing on GPCR disease drivers.
"With GPCR-targeting drugs accounting for more than 30% of all FDA approved therapeutics and 20% of all drugs being studied, this area of research and development has been incredibly fruitful and holds immense potential for the future," said Alan Fletcher, VP and GM of Life Sciences, PerkinElmer. "By adding these new assays to our already robust GPCR capabilities, we are giving researchers an end-to-end solution for continuing to unlock the role GPCRs play in disease so new and better therapeutics can be uncovered."
More on Boston Chron
For more information on the new kits and PerkinElmer's extensive line up of GPCR offerings please visit: https://www.perkinelmer.com/category/gpcr-research-reagents and https://horizondiscovery.com/en/screening/screening-libraries.
About PerkinElmer
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
The new assays, which enable researchers to use the preferred cell models of their choice, include the HTRF GTP Gi binding kit, the industry's first TR-FRET based assay for GTP binding; the B-arr2 recruitment kit; and HTRF total kits for B-Arrestin 1, B-Arrestin 2 and AP2. These assays will help scientists continue to better understand the important role GPCRs play in disease by studying the interaction, expression and potential modulation of intracellular proteins involved in GPCR signaling mechanisms.
More on Boston Chron
- Syxsense Announces Integration with Microsoft Office 365
- Charles River Laboratories Announces Strategic Partnership with Kibur Medical to Advance Preclinical Oncology Studies
- Launch of Trace One E-Sourcing Will Boost Retailers' Private Label Speed to Market
- Veristat Expands Global Service Capability in Biometrics with Acquisition of SQN Clinical
- City of Boston annual healthcare enrollment 2021
Further, when the new kits are leveraged as part of PerkinElmer's comprehensive range of GPCR solutions, users can fully characterize the GPCRs being studied -- from ligand binding with the Tag-Lite® platform, and 2nd messenger with the cAMP and IP-One™ kits, to downstream GPCR signaling with hundreds of available assays. With the recent acquisition of Horizon Discovery, the PerkinElmer portfolio also includes siRNA, shRNA, CRISPR guide RNA, and cDNA/ORF libraries, such as ON-TARGETplus™, SMARTvector™ and Edit-R™ and screening services, which help researchers better explore the impact of gene modulation and editing on GPCR disease drivers.
"With GPCR-targeting drugs accounting for more than 30% of all FDA approved therapeutics and 20% of all drugs being studied, this area of research and development has been incredibly fruitful and holds immense potential for the future," said Alan Fletcher, VP and GM of Life Sciences, PerkinElmer. "By adding these new assays to our already robust GPCR capabilities, we are giving researchers an end-to-end solution for continuing to unlock the role GPCRs play in disease so new and better therapeutics can be uncovered."
More on Boston Chron
- New Video Streaming Startup, Relax Scenes, Launches Indiegogo Campaign to Support Their Expansion
- American Tower Corporation to Present at the Raymond James 42nd Annual Institutional Investors Conference
- Changes to City of Boston Non-Medicare health plans
- Bronx DWI Lawyer Announces New Website
- Recording Artist "Cherne" Crystal Brown auditions for Sony Music, Atlantic Records and Capitol Records and it doesn't stop there
For more information on the new kits and PerkinElmer's extensive line up of GPCR offerings please visit: https://www.perkinelmer.com/category/gpcr-research-reagents and https://horizondiscovery.com/en/screening/screening-libraries.
About PerkinElmer
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
Filed Under: Business
0 Comments
Latest on Boston Chron
- Boston: Street sweeping, ticketing enforcement for expired inspection stickers and vehicle registration to resume
- City of Boston announces street sweeping; ticketing enforcement for expired inspection stickers and vehicle registration to resume
- Fennemore Names New Office Managing Partners, Practice Group Leaders & Chief Diversity Officer
- Wohler adds to their iVAM range with the launch of the iVAM2-2
- To Supply Chains and Beyond: Blue Yonder Expands Five-Year Partnership with Matter, Enlisting Full Suite of PR + Marketing Offerings
- Optimal Empowers Procurement Teams with Expert Best Practices
- Strategy Analytics: Service Robot Sales Volumes Surge as Covid-19 Pandemic Drives Demand.
- BEYOND GUANTANAMO: Louisiana Candidate for Congress blazes trail to freedom for U.S. political prisoners
- Reward Gateway Announces Two-Way Integration With Microsoft Teams to Enable Instant Employee Recognition
- The love of a teacher: Wilhelmina Crosson and Boston's first remedial studies program
- Boston: 67 projects totaling more than $25.5 million recommended for Community Preservation Act funding
- Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market
- 8th Annual American Reality TV Awards - ARTAS Official Nominations
- Boston: Mayor Walsh recommends 67 projects, totaling over $25.5 million in funding through Community Preservation Act
- Thirst for Japanese Whisky Strong as New Standards Set
- HD Physical Therapy Announces Two New Team Members
- Boston: Parks welcomes five full-time Rangers
- PEVO Sports Co. was recently awarded two GSA contracts with Brian Peterson and the Government Marketplace LLC team's assistance
- Skyhook to Provide E-911 and Location Positioning for Coolpad Americas Upcoming Mobile Phone Product
- eCollections Debt Management Platform Announces New Business Import Tool